<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563770</url>
  </required_header>
  <id_info>
    <org_study_id>QPHT-35</org_study_id>
    <nct_id>NCT01563770</nct_id>
  </id_info>
  <brief_title>Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen)</brief_title>
  <official_title>A Double Blind, Randomized Placebo-controlled Cross-over Study on the Cardiovascular Effects of Salvia Miltiorrhiza Extract (Danshen) in Patients With Hypertension and Hyperlipidemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Extracts of the plant Salvia miltiorrhiza (Danshen) have been used as traditional&#xD;
      Chinese medicine in the treatment of cardiovascular diseases, such as angina pectoris and&#xD;
      myocardial infarction. Several preclinical studies point towards promising effects of Danshen&#xD;
      on risk factors of atherosclerotic cardiovascular diseases, such as hyperlipidemia and&#xD;
      hypertension.&#xD;
&#xD;
      Objective: Our primary objective is to determine the effect of Salvia miltiorrhiza extract&#xD;
      (Danshen) on hyperlipidemia. Secondary objective is to investigate the effect of Danshen on&#xD;
      hypertension. Further objectives are to determine its effect on endothelial function,&#xD;
      oxidative stress, inflammation, hemostasis and hemorheology, and on insulin sensitivity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperlipidemia</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
    <description>Blood tests: lipids, in particular LDL-cholesterol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of oxidative stress</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular inflammation and inflammatory activation of adipose tissue</measure>
    <time_frame>after 4 weeks of treatment with danshen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostasis and hemorheological parameters</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>after 4 weeks of treatment with Danshen</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Hypertension</condition>
  <condition>Vasodilation</condition>
  <condition>Oxidative Stress</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Salvia miltiorrhiza extract (Danshen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>p.o. placebo, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Salvia miltiorrhiza extract</intervention_name>
    <description>3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks</description>
    <arm_group_label>Salvia miltiorrhiza extract (Danshen)</arm_group_label>
    <other_name>Danshen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 placebo capsules, twice daily for four consecutive weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 40-70&#xD;
&#xD;
          -  Women:&#xD;
&#xD;
               -  postmenopausal, or&#xD;
&#xD;
               -  use of contraceptive pill&#xD;
&#xD;
          -  Hyperlipidemia:&#xD;
&#xD;
               -  elevated level of triglycerides: &gt; 1.7 mmol/L, or&#xD;
&#xD;
               -  elevated level of LDL-cholesterol: &gt; 3.5 mmol/L&#xD;
&#xD;
          -  Hypertension:&#xD;
&#xD;
               -  systolic pressure &gt; 140 mm Hg, or&#xD;
&#xD;
               -  diastolic pressure &gt; 90 mm Hg&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  History of cardiovascular disease (myocard infarct, angina pectoris, CVA)&#xD;
&#xD;
          -  Diabetes mellitus, when treated with insulin&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hyperlipidemia which needs conventional treatment&#xD;
&#xD;
               -  elevated level of triglycerides: &gt; 8 mmol/L&#xD;
&#xD;
               -  elevated level of LDL-cholesterol: &gt; 5 mmol/L&#xD;
&#xD;
          -  Hypertension which needs conventional treatment:&#xD;
&#xD;
               -  systolic pressure &gt; 180 mm Hg&#xD;
&#xD;
               -  diastolic pressure &gt; 110 mm Hg&#xD;
&#xD;
          -  Clinically significant liver disease (3 times the upper normal limit of ALAT,ASAT)&#xD;
&#xD;
          -  Clinically significant anemia (male Hb &lt; 6,9 mmol/L, female &lt; 6,25 mmol/L)&#xD;
&#xD;
          -  Renal disease defined as MDRD &lt; 60 ml/min/1.73m2&#xD;
&#xD;
          -  Participation to any drug-investigation during the previous 90 days&#xD;
&#xD;
          -  Use of any herbal product during the previous 30 days&#xD;
&#xD;
          -  Concomitant (chronic) use of:&#xD;
&#xD;
        Medicinal products:&#xD;
&#xD;
          -  ACE-inhibitors, including a.o. captopril, enalapril, ramipril&#xD;
&#xD;
          -  AT1-antagonists, including a.o. losartan, valsartan, irbesartan&#xD;
&#xD;
          -  Statins, including a.o. simvastatin, rosuvastatin&#xD;
&#xD;
          -  Anticoagulant drugs, including a.o. aspirin&#xD;
&#xD;
          -  Calciumantagonists (including a.o. amlodipine, nifedipine, verapamil)&#xD;
&#xD;
          -  Use of more than 1 antihypertensive drug&#xD;
&#xD;
          -  High-dose antihypertensive medication (above defined daily dose)&#xD;
&#xD;
          -  Drugs which are exclusively metabolised by CYP3A4 (Flockhart DA; P450 drug interaction&#xD;
             table, including a.o. erythromycin, midazolam, cyclosporine, HIV antivirals)&#xD;
&#xD;
        Food products:&#xD;
&#xD;
          -  (Antioxidant) vitamin supplements&#xD;
&#xD;
          -  Other herbs, including a.o. St John's wort&#xD;
&#xD;
          -  Grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Rongen, MD, PhD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pauline Breedveld, PhD</last_name>
    <phone>+31243614597</phone>
    <email>p.breedveld@pharmtox.umcn.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pleun van Poppel, MD</last_name>
    <phone>+31243667211</phone>
    <email>p.vanpoppel@aig.umcn.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Breedveld, PhD</last_name>
      <phone>+31-243614597</phone>
      <email>p.breedveld@pharmtox.umcn.nl</email>
    </contact>
    <contact_backup>
      <last_name>Pleun van Poppel, MD</last_name>
      <phone>+31-243667211</phone>
      <email>p.vanpoppel@aig.umcn.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Gerard Rongen, MD, PhD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cees J. Tack, MD, PhD, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Vasodilation</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Hemostasis</keyword>
  <keyword>Hemorheology</keyword>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>Cardiovascular agents</keyword>
  <keyword>Salvia miltiorrhiza</keyword>
  <keyword>Danshen</keyword>
  <keyword>Danshen root extract</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Therapeutic Uses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

